Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAXIME AND DEXTROSE 3 9 IN PLASTIC CONTAINER versus ROCEPHIN W DEXTROSE IN PLASTIC CONTAINER.
CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER vs ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotaxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV every 4-6 hours; maximum 12 g/day.
1-2 g IV or IM once daily; maximum 4 g/day. For serious infections, 2 g IV every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 0.8-1.4 hours in adults with normal renal function; prolonged to 2.5-15 hours in renal impairment; clinical context: dosing interval adjustment required for CrCl <20 mL/min
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged up to 15 hours in elderly; significantly increased in renal impairment (up to 20-30 hours in ESRD).
Primarily renal (80-90% unchanged within 24 hours); biliary/fecal elimination accounts for <10%
Renal (33-67% unchanged) and biliary (40-50% unchanged and microbiologically inactive metabolite). Approximately 50% excreted in urine, 50% in feces.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic